Replies to post #79470 on Regen BioPharma Inc (RGBP)

[RoagTrader]

Everything Koos has done points to RGBP being set up for a buyout, nothing else makes sense especially going into clinical trials. We know the IP is very valuable and a large pharma will easily pay $1 billion+ to add it to their portfolio.

[Jack Torrance]

I agree totally. Intellectual property related to medical patents are a hard thing to valuate. If they are pre-clinical trials, they are understandably worth much less, because they only work in theory. In that case, the dollar value is pretty much a ball-park estimation based on future revenue potential and negotiations with the selling company. In the case of RGBP's patents, I think their pre-clinical trial value is somewhere in the $5 billion to $10 billion range, which would be roughly $1.50 per share. Just my opinion.

Also totally agree that RGBP is not set up to go into clinical trials any time soon. But if they did prove their tech does work in a clinical trial, then the value of the company goes WAY up. I'm talking $50 to $100 billion. Essentially making chemo and radiation therapy obsolete in most instances of tumorous cancer would be beyond colossal.